Uses and compositions for treatment of hidradenitis suppurativa (hs)
AssigneeAbbVie Biotechnology Ltd.
InventorsMartin M. OKUN, Thomas C. Harris
Life of this patent
Estimating the term…
Abstract
The invention provides methods, uses and compositions for the treatment of hidradenitis suppurativa. The invention describes methods and uses for treating hidradenitis suppurativa, wherein a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof, is used to treat hidradenitis suppurativa in a subject. Also described are methods for determining the efficacy of a TNFα inhibitor for treating hidradenitis suppurativa in a subject.
Claims34
A method for treating a subject having hidradenitis suppurativa (HS), the method comprising administering an isolated human anti-TNFα antibody, or an antigen binding portion thereof, to the subject according to a multiple variable dose regimen, such that HS is treated, wherein the multiple variable dose regimen comprises administering a first loading dose, administering a second loading dose which is less than the first loading dose, and administering a treatment dose which is less than the second loading dose, wherein the treatment dose is administered to the subject weekly.
A method for decreasing the number of inflammatory lesions (AN count) in a subject having HS, said method comprising systemically administering an isolated human anti-TNFα antibody, or an antigen binding portion thereof, to the subject, such that the AN count is decreased.
A kit for the treatment of HS in a subject, said kit comprising
- at least seven containers comprising an isolated human anti-TNFα antibody,or an antigen binding portion thereof, and
- instructions for administration of the anti-TNFα antibody,or antigen binding portion thereof, to a subject having HS.
Dependencies are inferred from the claim text.